2023 Partners

Find out more about each of our sponsors by reading their summary biographies or visiting their websites. To learn about our bespoke partnership opportunities and how you can get your brand in front of our dedicated neoantigen audience, view our why partner page, download the 2023 event guide or get in touch with us.

 

Personalis

EXPERTISE PARTNER:

Personalis, Inc. is a leader inadvanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample.

www.personalis.com

NEC Oncolmmunity

INDUSTRY PARTNER:

NEC OncoImmunity is a bioinformatics company offering proprietary machinelearning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. NEC OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalized cancer vaccines & cell therapies in clinically actionable timeframe.

www.oncoimmunity.com

almac

EXHIBITION PARTNER:

Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personlised cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.

www.almacgroup.com

 

LOGO PROVEPHARM_CMJN

EXHIBITION PARTNER:

Provepharm Life Solutions is a pharmaceutical and a CDMO company commercializing immunopeptide services since 2003. Pionner in the chemical synthesis of + 100 mer long peptide we delivered our first clinical batch of a 96-mer peptide in 2006. Specialized in microgram therapies we have developed a one-stopshop offer for the delivery of ready to use peptide-based drug products including conjugates. For personalized peptide vaccine programs we designed a GMP manufacturing process to deliver up to 40 neoantigens every 6 weeks.

www.provepharm.com

Get In Touch Now

kiran thomson

Kiran Thomson

Business Development Manager

Hanson Wade

sponsor@hansonwade.com